FibroScan (vibration-controlled transient elastography): Where does it stand in the United States practice

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 1, 2015, Pages 27-36

  Tapper, Elliot B ^a   Castera, Laurent ^b   Afdhal, Nezam H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BEAUJON HOSPITAL   (France)

Author keywords

Cirrhosis; Fibrosis; Hepatitis; Liver disease; Nonalcoholic fatty liver disease

Indexed keywords

ALCOHOL LIVER DISEASE; AREA UNDER THE CURVE; ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ELASTOGRAPH; ELASTOGRAPHY; ESOPHAGUS HEMORRHAGE; EUROPE; FATTY LIVER; GASTROENTEROLOGIST; HEPATITIS B; HEPATITIS C; HEPATOBILIARY DISEASE; HUMAN; INVASIVE PROCEDURE; LIVER DISEASE; LIVER FIBROSIS; MEDICAL PRACTICE; NONALCOHOLIC FATTY LIVER; POINT OF CARE TESTING; PORTAL HYPERTENSION; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SPLEEN DISEASE; SPLEEN STIFFNESS; UNITED STATES; VIBRATION CONTROLLED TRANSIENT ELASTOGRAPHY; VIRUS HEPATITIS; DIAGNOSTIC TEST; GASTROENTEROLOGY; HOSPITAL INFORMATION SYSTEM; LIVER DISEASES; PROCEDURES; VIBRATION;

DIAGNOSTIC TESTS, ROUTINE; ELASTICITY IMAGING TECHNIQUES; GASTROENTEROLOGY; HUMANS; LIVER DISEASES; POINT-OF-CARE SYSTEMS; UNITED STATES; VIBRATION;

EID: 84917677294     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.04.039     Document Type: Article

References (85)

1. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR 2012, 61:1-18. Centers for Disease Control.
2. Sandrin L., Fourquet B., Hasquenoph J.M., et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003, 29:1705-1713.
3. Fraquelli M., Rigamonti C., Casazza G., et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007, 56:968-973.
4. Roulot D., Czernichow S., Le Clésiau H., et al. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. JHepatol 2008, 48:606-613.
5. Castéra L., Foucher J., Bernard P.H., et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010, 51:828-835.
6. Sagir A., Erhardt A., Schmitt M., et al. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 2008, 47:592-595.
7. Tapper E.B., Cohen E.B., Patel K., et al. Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2012, 10:932-937.
8. Oliveri F., Coco B., Ciccorossi P., et al. Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases. World J Gastroenterol 2008, 14:6154-6162.
9. Arena U., Vizzutti F., Corti G., et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008, 47:380-384.
10. Kim K.M., Choi W.B., Park S.H., et al. Diagnosis of hepatic steatosis and fibrosis by transient elastography in asymptomatic healthy individuals: a prospective study of living related potential liver donors. JGastroenterol 2007, 42:382-388.
11. Millonig G., Reimann F.M., Friedrich S., et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 2008, 48:1718-1723.
12. Lebray P., Varnous S., Charlotte F., et al. Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency. Hepatology 2008, 48:2089.
13. Millonig G., Friedrich S., Adolf S., et al. Liver stiffness is directly influenced by central venous pressure. JHepatol 2010, 52:206-210.
14. Bordessoule D., Vidal E., Sautereau D., et al. Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool. Amyloid 2011, 18:19-24.
15. Berzigotti A., De Gottardi A., Vukotic R., et al. Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension. PLoS One 2013, 8:e58742.
16. Mederacke I., Wursthorn K., Kirschner J., et al. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Int 2009, 29:1500-1506.
17. Arena U., Lupsor Platon M., Stasi C., et al. Liver stiffness is influenced by a standardized meal in patients with chronic HCV hepatitis at different stages of fibrotic evolution. Hepatology 2013, 58:65-72.
18. Kettaneh A., Marcellin P., Douvin C., et al. Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. JHepatol 2007, 46:628-634.
19. Seeff L.B., Everson G.T., Morgan T.R., et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 2010, 8:877-883.
20. Bravo A.A., Sheth S.G., Chopra S. Liver biopsy. NEngl J Med 2001, 344:495-500.
21. Robert M., Sofair A.N., Thomas A., et al. Acomparison of hepatopathologists' and community pathologists' review of liver biopsy specimens from patients with hepatitis C. Clin Gastroenterol Hepatol 2009, 7. 335-338.
22. Bedossa P., Dargère D., Paradis V. Sampling variability of liverfibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
23. Friedrich-Rust M., Ong M.F., Martens S., et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008, 134:960-974.
24. Castéra L., Vergniol J., Foucher J., et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-350.
25. Zarski J.P., Sturm N., Guechot J., et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. JHepatol 2012, 56:55-62.
26. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012, 142:1293-1302.
27. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994, 20:15-20. The French METAVIR Cooperative Study Group.
28. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. JHepatol 1995, 22:696-699.
29. Ziol M., Handra-Luca A., Kettaneh A., et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005, 41:48-54.
30. Arena U., Vizzutti F., Abraldes J.G., et al. Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut 2008, 57:1288-1293.
31. Cardoso A.C., Carvalho-Filho R.J., Stern C., et al. Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. Liver Int 2012, 32:612-621.
32. Gara N., Zhao X., Kleiner D.E., et al. Discordance among transient elastography, aspartate aminotransferase to platelet ratio index, and histologic assessments of liver fibrosis in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2013, 11:303-308.
33. Afdhal N.H., Bacon B.R., Patel K., et al. Diagnosis accuracy of liver stiffness (FibroScan®) in patients with chronic viral hepatitis: results of a large USA cohort. Hepatology 2013, 58:278A-279A.
34. Coco B., Oliveri F., Maina A.M., et al. Transient elastography: a new surrogate marker of liver fibrosis influenced bymajorchanges of transaminases. JViral Hepat 2007, 14:360-369.
35. Wong G.L., Wong V.W., Choi P.C., et al. Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. Clin Gastroenterol Hepatol 2008, 6:1027-1035.
36. Verignol J., Foucher J., Castéra L., et al. Changes of non-invasive markers and FibroScan values during HCV treatment. JViral Hepat 2009, 16:132-140.
37. Hézode C., Castéra L., Roudot-Thoraval F., et al. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther 2011, 34:656-663.
38. Marcellin P., Ziol M., Bedossa P., et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009, 29:242-247.
39. Chon Y.E., Choi E.H., Song K.J., et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One 2012, 7:e44930.
40. Kim S.U., Seo Y.S., Cheong J.Y., et al. Factors that affect the diagnostic accuracy of liver fibrosis measurement by Fibroscan in patients with chronic hepatitis B. Aliment Pharmacol Ther 2010, 32:498-505.
41. Viganò M., Massironi S., Lampertico P., et al. Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B. Eur J Gastroenterol Hepatol 2010, 22:180-184.
42. Fung J., Lai C.L., Chan S.C., et al. Correlation of liver stiffness and histological features in healthy persons and in patients with occult hepatitis B, chronic active hepatitis B, or hepatitis B cirrhosis. Am J Gastroenterol 2010, 105:1116-1122.
43. Chan H.L., Wong G.L., Choi P.C., et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. JViral Hepat 2009, 16:36-44.
44. Festi D., Schiumerini R., Marzi L., et al. Review article: the diagnosis of non-alcoholic fatty liver disease-availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 2013, 37:392-400.
45. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55:2005-2023.
46. Kleiner D.E., Brunt E.M. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012, 32:3-13.
47. Castera L., Vilgrain V., Angulo P. Non invasive evalutation of NAFLD. Nat Rev Gastroenterol Hepatol 2013, 10:666-675.
48. Wong V.W., Vergniol J., Wong G.L., et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010, 51:454-462.
49. Wong V.W., Vergniol J., Wong G.L., et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012, 107:1862-1871.
50. Gaia S., Carenzi S., Barilli A.L., et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. JHepatol 2011, 54:64-71.
51. Petta S., Di Marco V., Cammà C., et al. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther 2011, 33:1350-1360.
52. de Ledinghen V., Vergniol J., Foucher J., et al. Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int 2010, 30:1043-1048.
53. De Lédinghen V., Wong V.W., Vergniol J., et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®. JHepatol 2012, 56:833-839.
54. Myers R.P., Pomier-Layrargues G., Kirsch R., et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012, 55:199-208.
55. Friedrich-Rust M., Hadji-Hosseini H., Kriener S., et al. Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis. Eur Radiol 2010, 20:2390-2396.
56. Bardou-Jacquet E., Legros L., Soro D., et al. Effect of alcohol consumption on liver stiffness measured by transient elastography. World J Gastroenterol 2013, 19:516-522.
57. Mueller S., Millonig G., Sarovska L., et al. Increased liver stiffness in alcoholic liver disease: differentiating fibrosis from steatohepatitis. World J Gastroenterol 2010, 16:966-972.
58. Gelsi E., Dainese R., Truchi R., et al. Effect of detoxification on liver stiffness assessed by Fibroscan® in alcoholic patients. Alcohol Clin Exp Res 2011, 35:566-570.
59. Trabut J.B., Thépot V., Nalpas B., et al. Rapid decline of liver stiffness following alcohol withdrawal in heavy drinkers. Alcohol Clin Exp Res 2012, 36:1407-1411.
60. Nahon P., Kettaneh A., Tengher-Barna I., et al. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. JHepatol 2008, 49:1062-1068.
61. Corpechot C., El Naggar A., Poujol-Robert A., et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006, 43:1118-1124.
62. Friedrich-Rust M., Müller C., Winckler A., et al. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers. JClin Gastroenterol 2010, 44:58-65.
63. Corpechot C., Carrat F., Poujol-Robert A., et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012, 56:198-208.
64. Castera L., Pinzani M., Bosch J. Non invasive evaluation of portal hypertension using transient elastography. JHepatol 2012, 56:696-703.
65. Shi K.Q., Fan Y.C., Pan Z.Z., et al. Transient elastography: a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. Liver Int 2013, 33:62-71.
66. Bureau C., Metivier S., Peron J.M., et al. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. Aliment Pharmacol Ther 2008, 27:1261-1268.
67. Malik R., Lai M., Sadiq A., et al. Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis. JGastroenterol Hepatol 2010, 25:1562-1568.
68. Robic M.A., Procopet B., Métivier S., et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. JHepatol 2011, 55:1017-1024.
69. Sporea I., Raţiu I., Sirli R., et al. Value of transient elastography for the prediction of variceal bleeding. World J Gastroenterol 2011, 17:2206-2210.
70. Kim S.U., Lee J.H., Kim D.Y., et al. Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS One 2012, 7:e36676.
71. Klibansky D.A., Mehta S.H., Curry M., et al. Transient elastography for predicting clinical outcomes in patients with chronic liver disease. JViral Hepat 2012, 19:e184-e193.
72. Singh S., Fujii L.L., Murad M.H., et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013, 11:1573-1584.
73. Stefanescu H., Grigorescu M., Lupsor M., et al. Spleen stiffness measurement using fibroscan for the noninvasive assessment of esophageal varices in liver cirrhosis patients. JGastroenterol Hepatol 2011, 26:164-170.
74. Colecchia A., Montrone L., Scaioli E., et al. Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology 2012, 143:646.
75. Sharma P., Kirnake V., Tyagi P., et al. Spleen stiffness in patients with cirrhosis in predicting esophageal varices. Am J Gastroenterol 2013, 108:1101-1107.
76. Sasso M., Tengher-Barna I., Ziol M., et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C. JViral Hepat 2012, 19:244-253.
77. Sasso M., Beaugrand M., de Ledinghen V., et al. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis-preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010, 36:1825-1835.
78. Becker L., Salameh W., Sferruzza A., et al. Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol 2009, 7:696-701.
79. Bonder A., Afdhal N.H. Biopsy no more: changing the screening and diagnostic algorithm for hepatitis C. Clin Gastroenterol Hepatol 2013, 11:309-310.
80. Castera L., Denis J., Babany G., et al. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines?. JHepatol 2007, 46:528-529.
81. Haute Autorité de Santé. Noninvasive methods for the evaluation of hepatic fibrosis/ cirrhosis: an update. Available at: Accessed August2008. http://www.has-sante.fr.
82. Mutimer D., Aghemo A., Diepolder H., et al. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014, 60:392-420.
83. Degos F., Perez P., Roche B., et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). JHepatol 2010, 53:1013-1021.
84. Roulot D., Costes J.L., Buyck J.F., et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 2011, 60:977-984.
85. Berzigotti A.L., Castera L. Update on ultrasound imaging of liver fibrosis. JHepatol 2013, 58:180-182.